These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26188511)

  • 21. In vitro modification of human centromere protein CENP-C fragments by small ubiquitin-like modifier (SUMO) protein: definitive identification of the modification sites by tandem mass spectrometry analysis of the isopeptides.
    Chung TL; Hsiao HH; Yeh YY; Shia HL; Chen YL; Liang PH; Wang AH; Khoo KH; Shoei-Lung Li S
    J Biol Chem; 2004 Sep; 279(38):39653-62. PubMed ID: 15272016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity.
    Merrill JC; Melhuish TA; Kagey MH; Yang SH; Sharrocks AD; Wotton D
    PLoS One; 2010 Jan; 5(1):e8794. PubMed ID: 20098713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
    González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
    Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitric oxide destabilizes Pias3 and regulates sumoylation.
    Qu J; Liu GH; Wu K; Han P; Wang P; Li J; Zhang X; Chen C
    PLoS One; 2007 Oct; 2(10):e1085. PubMed ID: 17987106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SIM-dependent enhancement of substrate-specific SUMOylation by a ubiquitin ligase in vitro.
    Parker JL; Ulrich HD
    Biochem J; 2014 Feb; 457(3):435-40. PubMed ID: 24224485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
    Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
    Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
    Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
    Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion.
    Kim ET; Kim KK; Matunis MJ; Ahn JH
    Biochem Biophys Res Commun; 2009 Oct; 388(1):41-5. PubMed ID: 19635459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
    Li Z; Wu S; Wang J; Li W; Lin Y; Ji C; Xue J; Chen J
    Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct functional modes of SUMOylation for retinoid X receptor alpha.
    Lee WP; Jena S; Rodriguez EP; O'Donovan SP; Wagner C; Jurutka PW; Thompson PD
    Biochem Biophys Res Commun; 2015 Aug; 464(1):195-200. PubMed ID: 26116533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation.
    Karaca E; Tozluoğlu M; Nussinov R; Haliloğlu T
    J Mol Biol; 2011 Mar; 406(4):620-30. PubMed ID: 21216249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sumoylated SnoN represses transcription in a promoter-specific manner.
    Hsu YH; Sarker KP; Pot I; Chan A; Netherton SJ; Bonni S
    J Biol Chem; 2006 Nov; 281(44):33008-18. PubMed ID: 16966324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells.
    Huang CH; Yang TT; Lin KI
    J Biomed Sci; 2024 Jan; 31(1):16. PubMed ID: 38280996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.
    Gocke CB; Yu H; Kang J
    J Biol Chem; 2005 Feb; 280(6):5004-12. PubMed ID: 15561718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger.
    Deng Z; Wan M; Sui G
    Mol Cell Biol; 2007 May; 27(10):3780-92. PubMed ID: 17353273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
    Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
    J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIASγ controls stability and facilitates SUMO-2 conjugation to CoREST family of transcriptional co-repressors.
    Sáez JE; Arredondo C; Rivera C; Andrés ME
    Biochem J; 2018 Apr; 475(8):1441-1454. PubMed ID: 29555846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
    Citro S; Chiocca S
    Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple domains in Siz SUMO ligases contribute to substrate selectivity.
    Reindle A; Belichenko I; Bylebyl GR; Chen XL; Gandhi N; Johnson ES
    J Cell Sci; 2006 Nov; 119(Pt 22):4749-57. PubMed ID: 17077124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.
    Truong K; Lee TD; Chen Y
    J Biol Chem; 2012 May; 287(19):15154-63. PubMed ID: 22403398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.